Many patients with atherosclerotic cardiovascular disease remain at risk of further cardiovascular events despite standard secondary prevention. Ongoing risk is driven by inflammation, cardiometabolic conditions, lipid abnormalities and clotting factors, highlighting the need for better identification, assessment and management in clinical practice.